关于 Venetoclax API

Product
  • CAS 编号

    1257044-40-8

  • API 技术

    高效力

  • 剂型

    口服固体/片剂

  • Dr Reddy's 开发状态

    可用的

  • 可用的法规申报文件

    USDMF

Mechanism of Action

Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.

Indication

VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

FAQs

Venetoclax API有哪些用途?
  • 用于治疗慢性淋巴细胞白血病(CLL)、小淋巴细胞淋巴瘤(SLL)和急性髓系白血病(AML)。

如何存储Venetoclax API?
  • 请将本品存放于原包装容器中,温度保持在 30°C (86°F) 或以下,并防潮。

使用 Venetoclax API 时应注意哪些事项?
  • 避免接种活疫苗

    监测肿瘤溶解综合征(TLS)

    确保充足的水分

目前Venetoclax有哪些剂型和规格?
  • 有口服片剂规格:10毫克、50毫克、100毫克

免责声明

本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patents Act (Bolar Exemption) and not for commercial sale.